Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...

Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and ...

U.S. Health and Human Services Secretary Robert Kennedy made his first appearance May 14 before the Senate Health, Education, ...

Small interfering RNA (siRNA) gained another vote of confidence, albeit back end-loaded, from big pharma as privately held ...

The metabotropic nucleotide receptor P2Y14 shows strong potential as a therapeutic target against various inflammatory ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a ...

April may not have brought rain to med-tech, but tariffs and financial uncertainty certainly dampened the enthusiasm for IPOs ...

Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to ...

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing ...

Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the ...